Conference Proceedings

Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.

Joaquin Mateo, Heather H Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Paul Kolinsky, Ada Balasopoulou, Claudia Bertan, Suzanne Carreira, Heather Thorne, Robert B Montgomery, Shahneen Kaur Sandhu, Mark A Rubin, Peter Nelson, Johann S De Bono

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018

Abstract

218 Background: CRPC is enriched for germline mutations in DNA damage repair genes (gDDRm). BRCA2 mutations (g BRCA2m) associate with poor prognosis from localized PC, but prognostic and predictive value for standard therapy in CRPC is unclear. We reviewed clinical outcome of 390 patients previously tested for gDDRm. Methods: Patient records were reviewed for 372 patients from 3 institutions (Royal Marsden UK, Weill-Cornell NY, University of Washington, WA) with gDDRm status previously published (Pritchard et al, NEJM 2016) and 18 g BRCA1/2m carriers from KConFab consortium (Australia). Baseline characteristics and survival were annotated. Response (PSA50%/RECIST) and PFS (RECIST/PSA progre..

View full abstract